Saturday, August 12, 2017 -- Gilead Sciences Inc.'s updated labeling for Epclusa has been approved by the U.S. Food and Drug Administration.Epclusa is an all-oral, pan-genotypic, once-daily single tablet regimen for the treatment of adults with chronic hepatitis C virus (HCV) infection. The updated labeling allows the drug to be used on patients co-infected with HIV.“HCV co-infection remains a major cause of morbidity in HIV-infected individuals. With this expanded use, Epclusa provides co-infected patients with a much needed one-pill-a-day regimen that works across all HCV genotypes and is compatible with widely-used antiretroviral regimens,” David Wyles, chief of the Division of Infectious Disease at the Denver Health Medical Center, said in a statement. “With Epclusa, physicians have an important new treatment option for their HCV/HIV
Wednesday, August 16, 2017 -- A recent study finds that the use of sofosbuvir-based direct-acting antivirals for HCV treatment was effective and well-tolerated in elderly patients.
Thursday, August 17, 2017 -- Health Canada approved Gilead’s Vosevi for treating patients with chronic hepatitis C with genotypes 1 through 6 previously treated with an NS5A inhibitor-containing regimen, or with genotypes 1 through 4 previously treated with sofosbuvir-containing regimen without an NS5A inhibitor, according to a press release.“The evolution of Gilead’s portfolio of HCV single-tablet regimens has been driven by our commitment to address previously unmet needs and put the possibility of cure within reach for as many HCV patient populations as possible,” Kennet Brysting, general manager of Gilead Canada, said in the release. “The approval of Vosevi in Canada completes our HCV portfolio and this will enable the company to commit to collaborative partnerships that will help drive progress towards the goal
Thursday, August 17, 2017 -- Health Canada approved AbbVie’s Maviret for treating adults with chronic hepatitis C for all genotypes, according to a press release. Maviret is designated for patients without cirrhosis and who are new to treatment.“With the approval of Maviret, we are proud to bring the hope of a new cure to people living with hepatitis C in Canada, reflecting AbbVie’s dedication to addressing critical unmet needs for patients,” Stéphane Lassignardie, general manager of AbbVie Canada, said in the release. “Maviret is designed to deliver a virologic cure for most HCV patients including those with specific treatment challenges. AbbVie will continue to work with local health authorities and stakeholders across Canada to get our treatment to as many patients as possible.”